lisata.com - LSTA Income before deduction of interest, taxes and amortization

Lisata Therapeutics (LSTA) is developing a drug delivery system for neoplasms, planning to monetize the technology through royalties from pharma behemoths. Innovations in molecular transport enable the company to benefit from licensing agreements. The EBITDA reflects profit dynamics, where 0.00 serves as the base parameter value. Expected results from clinical trials on solid tumors will act as the primary growth catalysts.

LSTA: Lisata Profit before payment of interest, taxes and amortization 11/23/2025 - 11/12/2026

Lisata Therapeutics, Inc. - analytical breakdowns and key metrics (LSTA)

- market value and analyst target forecast:

Market Price Lisata Therapeutics Inc.|LSTA - Consensus Target

- issuer market value details:

Market Value Lisata Therapeutics|LSTA - Total Company Value

- book capitalization information:

Share Book Value Lisata Therapeutics|LSTA - Company Book Value|Market Value to Book Value Ratio lisata.com|LSTA - Company Total Assets

- debt level and financial liquidity data:

- earnings and valuation multiples information:

LSTA - Company Net Income|Future Profit Lisata Therapeutics|LSTA - Price to Earnings Ratio|Market Cap to Projected Earnings Lisata Therapeutics Inc.|LSTA - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lisata Therapeutics|LSTA - Operating profit EBITDA|Net earnings per share for the last four quarters Lisata Therapeutics|LSTA - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months lisata.com|LSTA - Earnings growth in current year|Earnings growth forecast for next year Lisata Therapeutics

Summary company analytics:Lisata Therapeutics, LSTA

Lisata Therapeutics (LSTA) specializes in developing drugs to increase tumor permeability for the treatment of severe forms of cancer via insurance payments. By analyzing the earnings before interest, taxes, depreciation, and amortization (EBITDA), an investor can see the actual cash balance from operating activities, which reflects the real balance of supply and demand, allowing for an assessment of the business's fundamental ability to generate cash regardless of debt and tax burdens.

Competitors of Lisata Therapeutics (LSTA)

Geron Bio (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BCYC (bicycletherapeutics.com)|CytomX Therapeutics, Inc. (CTMX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CATX (Perspective Therapeutics, Inc.)|Profit before payment of interest, taxes and amortization Genelux Corp.|Profit before payment of interest, taxes and amortization MOLN|Operating profit EBITDA ONCY|Operating profit EBITDA moleculin.com (MBRX)|Galera Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Inc)